Advertisement

The Effect of Opioid Therapy on Endocrine Function

      Abstract

      Opioids are an established option in the analgesic armamentarium for managing moderate-to-severe chronic pain. Long-term opioid use, however, is associated with several potential adverse effects and toxicities, such as peripheral edema, immune suppression, hyperalgesia, sleep apnea, and changes in endocrine function, many of which are not fully appreciated. Opioid endocrinopathy can greatly affect patients, causing reduced sexual function, decreased libido, infertility, mood disorders, osteoporosis, and osteopenia. Furthermore, although opioid endocrinopathy appears to be common, many patients do not report their symptoms, thus causing this adverse effect to go unnoticed and without clinical monitoring, particularly in patients chronically taking the equivalent of ≥100 mg of morphine daily. Indeed, diagnosing hypogonadism as opioid-related can be challenged by other influences on endocrine function, such as pain pathophysiology, comorbidities, other drug therapies, and patient age. Management options for opioid endocrinopathy include discontinuing opioid therapy, reducing the opioid dose, switching to a different opioid, and hormone supplementation.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to The American Journal of Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Harris J.D.
        Management of expected and unexpected opioid-related side effects.
        Clin J Pain. 2008; 24: S8-S13
        • Katz N.
        • Mazer N.A.
        The impact of opioids on the endocrine system.
        Clin J Pain. 2009; 25: 170-175
        • Gardner-Nix J.
        Opioids causing peripheral edema.
        J Pain Symptom Manage. 2002; 23: 453-455
        • Ninković J.
        • Roy S.
        Role of the mu-opioid receptor in opioid modulation of immune function.
        Amino Acids. 2011; Dec 15; ([Epub ahead of print])
        • Krantz M.J.
        • Martin J.
        • Stimmel B.
        • Mehta D.
        • Haigney M.C.
        QTc interval screening in methadone treatment.
        Ann Intern Med. 2009; 150: 387-395
        • Lo B.
        • Rubenfeld G.
        Palliative sedation in dying patients: “we turn to it when everything else hasn't worked.”.
        JAMA. 2005; 294: 1810-1816
        • Mercadante S.
        • Ferrera P.
        • Villari P.
        • Arcuri E.
        Hyperalgesia: an emerging iatrogenic syndrome.
        J Pain Symptom Manage. 2003; 26: 769-775
        • Guilleminault C.
        • Cao M.
        • Yue H.J.
        • Chawla P.
        Obstructive sleep apnea and chronic opioid use.
        Lung. 2010; 188: 459-468
        • Daniell H.W.
        Hypogonadism in men consuming sustained-action oral opioids.
        J Pain. 2002; 3: 377-384
        • Saunders K.W.
        • Dunn K.M.
        • Merrill J.O.
        • et al.
        Relationship of opioid use and dosage levels to fractures in older chronic pain patients.
        J Gen Intern Med. 2010; 25: 310-315
        • Hallinan R.
        • Byrne A.
        • Agho K.
        • McMahon C.
        • Tynan P.
        • Attia J.
        Erectile dysfunction in men receiving methadone and buprenorphine maintenance treatment.
        J Sex Med. 2008; 5: 684-692
        • Mulligan T.
        • Frick M.F.
        • Zuraw Q.C.
        • Stemhagen A.
        • McWhirter C.
        Prevalence of hypogonadism in males aged at least 45 years: the HIM study.
        Int J Clin Pract. 2006; 60: 762-769
        • Dobs A.S.
        • Dempsey M.A.
        • Ladenson P.W.
        • Polk B.F.
        Endocrine disorders in men infected with human immunodeficiency virus.
        Am J Med. 1988; 84: 611-616
        • Dobs A.S.
        Androgen therapy in AIDS wasting.
        Baillieres Clin Endocrinol Metab. 1998; 12: 379-390
        • Guay A.
        • Seftel A.D.
        • Traish A.
        Hypogonadism in men with erectile dysfunction may be related to a host of chronic illnesses.
        Int J Impot Res. 2010; 22: 9-19
        • Farney R.J.
        • Walker J.M.
        • Cloward T.V.
        • Rhondeau S.
        Sleep-disordered breathing associated with long-term opioid therapy.
        Chest. 2003; 123: 632-639
        • Webster L.R.
        • Choi Y.
        • Desai H.
        • Webster L.
        • Grant B.J.
        Sleep-disordered breathing and chronic opioid therapy.
        Pain Med. 2008; 9: 425-432
        • Colameco S.
        • Coren J.S.
        Opioid-induced endocrinopathy.
        J Am Osteopath Assoc. 2009; 109: 20-25
        • Ballantyne J.C.
        • Mao J.
        Opioid therapy for chronic pain.
        N Engl J Med. 2003; 349: 1943-1953
        • Daniell H.W.
        Opioid endocrinopathy in women consuming prescribed sustained-action opioids for control of nonmalignant pain.
        J Pain. 2008; 9: 28-36
        • Ragni G.
        • De Lauretis L.
        • Bestetti O.
        • Sghedoni D.
        • Gambaro V.
        Gonadal function in male heroin and methadone addicts.
        Int J Androl. 1988; 11: 93-100
        • Rasheed A.
        • Tareen I.A.
        Effects of heroin on thyroid function, cortisol and testosterone level in addicts.
        Pol J Pharmacol. 1995; 47: 441-444
        • Malik S.A.
        • Khan C.
        • Jabbar A.
        • Iqbal A.
        Heroin addiction and sex hormones in males.
        J Pak Med Assoc. 1992; 42: 210-212
        • Mendelson J.H.
        • Mello N.K.
        Plasma testosterone levels during chronic heroin use and protracted abstinence: a study of Hong Kong addicts.
        Clin Pharmacol Ther. 1975; 17: 529-533
        • Cicero T.J.
        • Bell R.D.
        • Wiest W.G.
        • Allison J.H.
        • Polakoski K.
        • Robins E.
        Function of the male sex organs in heroin and methadone users.
        N Engl J Med. 1975; 292: 882-887
        • Mendelson J.H.
        • Mendelson J.E.
        • Patch V.D.
        Plasma testosterone levels in heroin addiction and during methadone maintenance.
        J Pharmacol Exp Ther. 1975; 192: 211-217
        • Finch P.M.
        • Roberts L.J.
        • Price L.
        • Hadlow N.C.
        • Pullan P.T.
        Hypogonadism in patients treated with intrathecal morphine.
        Clin J Pain. 2000; 16: 251-254
        • Abs R.
        • Verhelst J.
        • Maeyaert J.
        • et al.
        Endocrine consequences of long-term intrathecal administration of opioids.
        J Clin Endocrinol Metab. 2000; 85: 2215-2222
        • Roberts L.J.
        • Finch P.M.
        • Pullan P.T.
        • Bhagat C.I.
        • Price L.M.
        Sex hormone suppression by intrathecal opioids: a prospective study.
        Clin J Pain. 2002; 18: 144-148
        • Rhodin A.
        • Stridsberg M.
        • Gordh T.
        Opioid endocrinopathy: a clinical problem in patients with chronic pain and long-term oral opioid treatment.
        Clin J Pain. 2010; 26: 374-380
        • Fraser L.A.
        • Morrison D.
        • Morley-Forster P.
        • et al.
        Oral opioids for chronic non-cancer pain: higher prevalence of hypogonadism in men than in women.
        Exp Clin Endocrinol Diabetes. 2009; 117: 38-43
        • Rajagopal A.
        • Vassilopoulou-Sellin R.
        • Palmer J.L.
        • Kaur G.
        • Bruera E.
        Hypogonadism and sexual dysfunction in male cancer survivors receiving chronic opioid therapy.
        J Pain Symptom Manage. 2003; 26: 1055-1061
        • Rajagopal A.
        • Vassilopoulou-Sellin R.
        • Palmer J.L.
        • Kaur G.
        • Bruera E.
        Symptomatic hypogonadism in male survivors of cancer with chronic exposure to opioids.
        Cancer. 2004; 100: 851-858
        • Daniell H.W.
        Opioid osteoporosis [letter].
        Arch Intern Med. 2004; 164 (author reply 338): 338
        • Fortin J.D.
        • Bailey G.M.
        • Vilensky J.A.
        Does opioid use for pain management warrant routine bone mass density screening in men?.
        Pain Physician. 2008; 11: 539-541
        • Kim T.W.
        • Alford D.P.
        • Malabanan A.
        • Holick M.F.
        • Samet J.H.
        Low bone density in patients receiving methadone maintenance treatment.
        Drug Alcohol Depend. 2006; 85: 258-262
        • Abrahamsen B.
        • Brixen K.
        Mapping the prescriptiome to fractures in men—a national analysis of prescription history and fracture risk.
        Osteoporos Int. 2009; 20: 585-597
        • Kinjo M.
        • Setoguchi S.
        • Schneeweiss S.
        • Solomon D.H.
        Bone mineral density in subjects using central nervous system-active medications.
        Am J Med. 2005; 118: 1414.e7-1414.e12
        • Ensrud K.E.
        • Blackwell T.
        • Mangione C.M.
        • et al.
        Central nervous system active medications and risk for fractures in older women.
        Arch Intern Med. 2003; 163: 949-957
        • Miller K.K.
        • Klibanski A.
        Clinical review 106: amenorrheic bone loss.
        J Clin Endocrinol Metab. 1999; 84: 1775-1783
        • Pérez-Castrillón J.L.
        • Olmos J.M.
        • Gomez J.J.
        • et al.
        Expression of opioid receptors in osteoblast-like MG-63 cells, and effects of different opioid agonists on alkaline phosphatase and osteocalcin secretion by these cells.
        Neuroendocrinology. 2000; 72: 187-194
        • Rosen H.
        • Krichevsky A.
        • Bar-Shavit Z.
        The enkephalinergic osteoblast.
        J Bone Miner Res. 1998; 13: 1515-1520
        • Rico H.
        • Costales C.
        • Cabranes J.A.
        • Escudero M.
        Lower serum osteocalcin levels in pregnant drug users and their newborns at the time of delivery.
        Obstet Gynecol. 1990; 75: 998-1000
        • Forman L.J.
        • Tingle V.
        • Estilow S.
        • Cater J.
        The response to analgesia testing is affected by gonadal steroids in the rat.
        Life Sci. 1989; 45: 447-454
        • Pednekar J.R.
        • Mulgaonker V.K.
        Role of testosterone on pain threshold in rats.
        Indian J Physiol Pharmacol. 1995; 39: 423-424
        • Stoffel E.C.
        • Ulibarri C.M.
        • Craft R.M.
        Gonadal steroid hormone modulation of nociception, morphine antinociception and reproductive indices in male and female rats.
        Pain. 2003; 103: 285-302
        • Terner J.M.
        • Barrett A.C.
        • Grossell E.
        • Picker M.J.
        Influence of gonadectomy on the antinociceptive effects of opioids in male and female rats.
        Psychopharmacology (Berl). 2002; 163: 183-193
        • Daniell H.W.
        • Lentz R.
        • Mazer N.A.
        Open-label pilot study of testosterone patch therapy in men with opioid-induced androgen deficiency.
        J Pain. 2006; 7: 200-210
        • Miller K.
        • Corcoran C.
        • Armstrong C.
        • et al.
        Transdermal testosterone administration in women with acquired immunodeficiency syndrome wasting: a pilot study.
        J Clin Endocrinol Metab. 1998; 83: 2717-2725
        • Palm S.
        • Moenig H.
        • Maier C.
        Effects of oral treatment with sustained release morphine tablets on hypothalamic-pituitary-adrenal axis.
        Methods Find Exp Clin Pharmacol. 1997; 19: 269-273
        • Allolio B.
        • Schulte H.M.
        • Deuss U.
        • Kallabis D.
        • Hamel E.
        • Winkelman W.
        Effect of oral morphine and naloxone on pituitary-adrenal response in man induced by human corticotropin-releasing hormone.
        Acta Endocrinol (Copenh). 1987; 114: 509-514
        • Daniell H.W.
        DHEAS deficiency during consumption of sustained-action prescribed opioids: evidence for opioid-induced inhibition of adrenal androgen production.
        J Pain. 2006; 7: 901-907
        • Morley J.E.
        • Perry III, H.M.
        • Kevorkian R.T.
        • Patrick P.
        Comparison of screening questionnaires for the diagnosis of hypogonadism.
        Maturitas. 2006; 53: 424-429
        • Bhasin S.
        • Cunningham G.R.
        • Hayes F.J.
        • et al.
        Testosterone therapy in adult men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline.
        J Clin Endocrinol Metab. 2006; 91: 1995-2010
        • Bhasin S.
        • Cunningham G.R.
        • Hayes F.J.
        • et al.
        • Endocrine Society Task Force
        Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline.
        J Clin Endocrinol Metab. 2010; 95: 2536-2559
        • Rosner W.
        • Vesper H.
        • Endocrine Society; American Association for Clinical Chemistry; American Association of Clinical Endocrinologists; Androgen Excess/PCOS Society; American Society for Bone and Mineral Research; American Society for Reproductive Medicine; American Urological Association; Association of Public Health Laboratories; Endocrine Society; Laboratory Corporation of America; North American Menopause Society; Pediatric Endocrine Society
        Toward excellence in testosterone testing: a consensus statement.
        J Clin Endocrinol Metab. 2010; 95: 4542-4548
        • Wang C.
        • Nieschlag E.
        • Swerdloff R.
        • et al.
        • International Society of Andrology (ISA); International Society for the Study of Aging Male (ISSAM); European Association of Urology (EAU); European Academy of Andrology (EAA); American Society of Andrology (ASA)
        Investigation, treatment, and monitoring of late-onset hypogonadism in males: ISA, ISSAM, EAU, EAA, and ASA recommendations.
        J Androl. 2009; 30: 1-9
        • Wang C.
        • Harnett M.
        • Dobs A.S.
        • Swerdloff R.S.
        Pharmacokinetics and safety of long-acting testosterone undecanoate injections in hypogonadal men: an 84-week phase III clinical trial.
        J Androl. 2010; 31: 457-465
        • Rhoden E.L.
        • Morgentaler A.
        Risks of testosterone-replacement therapy and recommendations for monitoring.
        N Engl J Med. 2004; 350: 482-492
        • Kaufman J.M.
        • Graydon R.J.
        Androgen replacement after curative radical prostatectomy for prostate cancer in hypogonadal men.
        J Urol. 2004; 172: 920-922
        • Agarwal P.K.
        • Oefelein M.G.
        Testosterone replacement therapy after primary treatment for prostate cancer.
        J Urol. 2005; 173: 533-536
        • Khera M.
        • Grober E.D.
        • Najari B.
        • et al.
        Testosterone replacement therapy following radical prostatectomy.
        J Sex Med. 2009; 6: 1165-1170
        • Sarosdy M.F.
        Testosterone replacement for hypogonadism after treatment of early prostate cancer with brachytherapy.
        Cancer. 2007; 109: 536-541
        • Morgentaler A.
        • Lipshultz L.I.
        • Bennett R.
        • Sweeney M.
        • Avila Jr, D.
        • Khera M.
        Testosterone therapy in men with untreated prostate cancer.
        J Urol. 2011; 185: 1256-1260
        • Basaria S.
        • Coviello A.D.
        • Travison T.G.
        • et al.
        Adverse events associated with testosterone administration.
        N Engl J Med. 2010; 363: 109-122
        • Hallinan R.
        • Byrne A.
        • Agho K.
        • McMahon C.G.
        • Tynan P.
        • Attia J.
        Hypogonadism in men receiving methadone and buprenorphine maintenance treatment.
        Int J Androl. 2009; 32: 131-139
        • Bliesener N.
        • Albrecht S.
        • Schwager A.
        • Weckbecker K.
        • Lichtermann D.
        • Klingmüller D.
        Plasma testosterone and sexual function in men receiving buprenorphine maintenance for opioid dependence.
        J Clin Endocrinol Metab. 2005; 90: 203-206
        • Fine P.G.
        • Portenoy R.K.
        • Ad Hoc Expert Panel on Evidence Review and Guidelines for Opioid Rotation
        Establishing “best practices” for opioid rotation: conclusions of an expert panel.
        J Pain Symptom Manage. 2009; 38: 418-425